Forty-Five Years of Research and Progress in Breast Cancer: Progress for Some, Disparities for Most

Ilir Hoxha, MD, PhD; Dafina Ademi Islami, MD; Glorieuse Uwizeye, PhD; Victoria Forbes, MD, MS; and Mary D. Chamberlin, MD

Gains in Breast Cancer Treatment Unavailable for Most

Impressive gains in breast cancer research and treatment have been made over the past 45 years in high-income countries. Many women are now cured with a simple lumpectomy, minimal lymph node surgery, and targeted or endocrine therapy. However, this progress is in stark contrast to what exists in low- and middle-income countries (LMICs) where women have a higher burden of breast cancer mortality and significantly poorer quality of life after breast cancer treatment. Although the death rate from breast cancer has dropped by 40% between 1989 and 2015 across the United States, breast cancer mortality has been steadily rising since 1999. Wide global variation in breast cancer mortality again highlights that not all countries have achieved the same success. In fact, most of the advances since the 1970s in the United States, such as screening mammography, radiotherapy, antihuman epidermal growth factor receptor 2 therapy, bone-directed therapy, and other targeted therapies, are still not available for most women with breast cancer (Table 1, Fig 1). Breast reconstruction surgery, chemoprevention, and genomics are similarly inaccessible. When mastectomy is the only option, there are many fears and misconceptions and little incentive for women to seek earlier medical care. Since much of the improvement in mortality is now being credited to systemic therapies, it may be time to rethink the conventional wisdom where breast cancer treatment equals mastectomy or lumpectomy plus radiation.

Care Patterns in Different Countries

By the time most women in low- or middle-resource settings pursue medical care, breast cancer is often locally advanced or metastatic. Early detection is hindered by the lack of access to regular preventive primary care and the lack of awareness about early signs of breast cancer. Mastectomy is unfortunately still the king in many places, even when there is increasing access to systemic therapies such as aromatase inhibitors, tamoxifen, or chemotherapy, which can be used before surgery to try to avoid mastectomy. In areas where there is limited access to radiation, treatment is the same regardless of the stage and frequently includes mastectomy, chemotherapy, and hormone therapy, with all the toxicity, stigma, and disability associated with those treatments. The African Breast Cancer—Disparities in Outcomes study, a multicountry prospective cohort study, found that mastectomies outnumbered breast-conserving surgery in all participating countries and that at least 30% of deaths were preventable through downstaging and improvements in treatment. Similar situations can be found in Europe, for example, in Kosovo, an upper-middle-income country with a population of 1.8 million located in Southeastern Europe. Although historically speaking breast cancer treatment started many years earlier, the first oncology clinic was established within the University Clinical Center of Kosovo at the end of 2010. There, patients with cancer start specific oncology treatment without having to leave the country. In 2013, radiotherapy treatment began, which increases the opportunities for breast conservation or improved survival after mastectomy; however, even in 2019, 83% of women were still treated with mastectomy and only 17% had breast conservation. All services at the oncology clinic for patients with cancer are government-subsidized and free of charge. Every year, around 400 new cases of breast cancer are diagnosed. Late diagnosis and a large number of advanced cases at the time of diagnosis are still common. In 2019, 44% of women with breast cancer were diagnosed in stage III and IV and 56% in stage I and II of the disease. Despite the fact that 56% of women are diagnosed in stage I and II, mastectomy is still performed in most of them. Treatment with chemotherapy, human epidermal growth factor receptor 2–targeted therapy, or hormone therapy for breast cancer in Kosovo is available but remains challenging because of supply shortages. The challenges in breast cancer treatment are not unique to a particular country, region, or continent. They are systemic throughout the globe. Many countries have been trying to address it in different ways. For example, in Rwanda, a low-income country of 12.5 million in East Africa, the Ministry of Health in collaboration with US institutions established the Butaro Cancer Center of Excellence (BCCOE), Rwanda’s first public cancer facility in the country. Breast cancer is the most common cancer treated there, with approximately 1,800 cases
In Honduras, breast cancer is the most common cancer of women and a common cause of death. Although data are scarce, some reports suggest that 78% of breast cancers diagnosed there are stage III or IV.16 There is limited access to cancer education, screening, and treatment in general, but community-based educational programs and opportunistic screening campaigns have improved cancer knowledge in cervical and breast cancers. Community participation in these programs is especially high when they are advertised by local community leaders, with food and transportation to a central village provided.17,18 To conclude, the situation in dealing with breast cancer treatment is similar in many other LMIC countries although details and circumstances vary widely.

What Else Can be Done?

Health care depends on funding and resources, but funding levels in LMIC countries are unlikely to change soon and in many places, are subject to political changes in government. The challenge is what can be done with the current resources and funding. Resource-stratified guidelines are increasingly available and are a great first step in trying to address this issue.19 Such guidelines provide an opportunity to learn and use state-of-the-art comprehensive guidelines while considering real-time resources available in the social context and needs of the country. The National Comprehensive Cancer Network (NCCN) framework and Breast Health Global Initiative 2005 guidelines20,21 are among noted examples that should be given consideration.

If optimal resources and infrastructure are not available to achieve significant improvements in mortality, then the focus should be on which interventions make the most impact with the least impact on quality of life. Quality of life may improve simply by improving involvement of patients in the clinical decision-making process using data to educate and inform. Since a large amount of breast cancer

| TABLE 1. Breast Cancer Treatment and Year | United States | Rwanda | Kosovo |
|-------------------------------------------|---------------|--------|--------|
| Breast-conserving surgery                 | 1970          | 2014   | 2000   |
| Sentinel node biopsy                      | 1995          | NA     | NA     |
| Breast reconstruction                     | 2000          | 2015   | 2014   |
| Tamoxifen                                 | 1970          | 2012   | 1990   |
| Aromatase inhibitor                       | 1990          | 2012   | 2000   |
| Cobalt RT                                 | 1960          | NA     | NA     |
| Linear accelerator                        | 1980          | 2018   | 2012   |
| Doxorubicin                               | 1980          | 2012   | 2000   |
| Cyclophosphamide                          | 1960          | 2012   | 2000   |
| Paclitaxel                                | 1990          | 2012   | 2004   |
| Trastuzumab                               | 2000          | 2012   | 2008   |

Abbreviations: NA, not available; RT, radiotherapy.

*Private pay only.

Source: Hortobagyi1 and personal correspondence (G. Uwizeye and D. Ademi, June 2020).
treatment falls within the domain of preference-sensitive care, ie, care where preferences of women are taken into account in clinical decisions, introducing shared medical decision making may be beneficial. Such tools would not involve substantial costs and would engage women in treatment decisions. Data from early breast cancer trials in the 1970s are still highly applicable to the resources available in many LMICs and could provide data to support a shared decision-making approach where a woman may choose lumpectomy rather than mastectomy even if radiation is not readily available. The data on lumpectomy and whole breast radiation versus lumpectomy alone from the Early Breast Cancer Trialists’ Collaborative Group meta-analysis report a 16% reduction in risk of in-breast recurrence with radiation but only a 4% improvement in the 15-year risk of death for all participants. For the node-positive group, a more likely scenario in LMICs, there was a 21.5% reduction in recurrence over 10 years because of radiation, but death from breast cancer is only reduced by 9%. Increasing access to modern systemic therapies throughout the developing countries could use current medication distribution infrastructure, and rates of recurrence and death would further improve with training for optimal delivery of systemic therapy. In countries where delays in seeking and completing care are common and delays more than 3 months have been shown to correlate with poor outcomes, the absolute benefits of each modality of treatment are likely further reduced. A woman may choose treatment that results in a better short-term outcome with a higher long-term risk of recurrence if the risks and benefits are clearly explained and mastectomy and chemotherapy translate to significant psychosocial suffering such as abandonment, divorce, or financial and social destitution. The ABC-DO study found that the increased mortality in older women was entirely due to background mortality from other causes. Shared clinical decision making may be an accessible, inexpensive intervention to aid women in making decisions about breast cancer. Improving women’s understanding of the situation will improve the management and treatment of breast cancer.

Another useful example from high-income countries derives from prediction tools such as UKPredict that enables a shared decision-making conversation with patients. A 65-year-old postmenopausal woman in the United Kingdom with a 3-cm breast cancer and one positive lymph node has a 68% 10-year survival, compared with an 87% 10-year survival for the same woman without breast cancer. Survival can be improved by 6% with hormone therapy and 5% with chemotherapy, a reasonable incentive to proceed with hormone therapy and chemotherapy. To apply this tool, which was validated in a high-income country, to a LMIC requires many modifications. First and foremost, the 10-year life expectancy of a 65-year-old woman with or without breast cancer is much lower, as the average life expectancy is 18 years shorter in LMICs compared with developed countries according to recent WHO updates. Second, if radiation is not available, survival with surgery alone is reduced especially when optimal management includes postmastectomy radiation, and the benefits from hormone therapy and chemotherapy may not only be increased when available but also be reduced by delays in care or drug shortages. Nomograms for estimating the benefit of radiation in the elderly with stage II and III breast cancer have been developed, which also assist in showing the absolute benefits of radiation with respect to comorbidities and life expectancy. Increasingly, in the United States and other western countries, women over 65 years are opting for breast conservation without radiation when treated with hormone therapy. Much of the improvement in mortality in high-income countries is attributed to targeted therapy and chemotherapy, and many of these drugs have been added to the WHO Essential Medicines List. Drug availability is still suboptimal in low- and middle-income countries but if available could have a significant impact on survival and quality of life. Nomograms for LMICs that take into account the emerging data on access and delays in care, therapy options, and life expectancy are urgently needed to assist with decision making. Such methods would help to prevent additional suffering until earlier detection and access to care can be improved. However, they should be adopted and validated to the LMIC setting.

The path to addressing breast cancer patient quality of life and mortality in each country is not a straightforward exercise, but rather an effort that needs to be constructed around the specifics and resources of each country. As breast cancer outcomes improve in some parts of the world, access to better therapies will vary, as illustrated in our examples from Rwanda and Kosovo. Tools to help determine and explain the relative impacts of each therapy in a prognostic and predictive format in real time will improve the quality of life of women with breast cancer around the world. Research to identify quality measures for breast cancer care is invaluable and must be incorporated into these models as countries grapple with the burden of cancer. Such measures will vary by population and health care system and should be carefully weighed against cultural and quality of life factors associated with breast cancer treatment to improve outcomes. The resource-stratified treatment tables and process metrics developed by the Breast Health Global Initiative and others provide structures for a comprehensive approach to set priorities deliberately to establish a minimum standard of care with the rational and equitable use of existing resources. The burden of breast cancer in LMICs needs a holistic approach that includes the development of oncologic infrastructure, screening, shared decision making and awareness among women and reduction of risk factors.
AFFILIATIONS
1 The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth, Lebanon, NH
2 Oncology Clinic, University Clinical Center of Kosovo, Pristina, Kosovo
3 Society of Fellows, Department of Anthropology, Dartmouth College, Hanover, NH
4 Present affiliation: Arthur Labatt Family School of Nursing, Western University, London, Ontario, Canada
5 University of Connecticut Health Center, Farmington, CT
6 Department of Hematology-Oncology, Geisel School of Medicine at Dartmouth, Hanover, NH

CORRESPONDING AUTHOR
Mary D. Chamberlin, MD, Dartmouth-Hitchcock Medical Center, 1 Medical Center Dr, Lebanon, NH 03756; e-mail: mary.d.chamberlin@hitchcock.org.

PRIOR PRESENTATION
Presented at International Cancer Education Conference, virtual, October 12-16, 2021.

AUTHOR CONTRIBUTIONS
Conception and design: Ilir Hoxha, Glorieuse Uwizeye, Victoria Forbes, Mary D. Chamberlin
Financial support: Mary D. Chamberlin
Administrative support: Ilir Hoxha, Mary D. Chamberlin
 Provision of study materials or patients: Ilir Hoxha, Mary D. Chamberlin
Collection and assembly of data: Ilir Hoxha, Daflina Ademi Islami, Glorieuse Uwizeye, Mary D. Chamberlin
Data analysis and interpretation: Ilir Hoxha, Glorieuse Uwizeye, Mary D. Chamberlin
Manuscript writing: All authors

REFERENCES
1. Hortobagyi GN: Breast cancer: 45 Years of research and progress. J Clin Oncol 38:2454-2462, 2020
2. Cazap E, Magrath I, Kingham TP, et al: Structural barriers to diagnosis and treatment of cancer in low- and middle-income countries: The urgent need for scaling up. J Clin Oncol 34:14-16, 2016
3. Bellanger M, Zeinomar N, Tehranifar P, et al: Are global breast cancer incidence and mortality patterns related to country-specific economic development and prevention strategies? J Glob Oncol 4:1-16, 2018
4. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2019. CA Cancer J Clin 69:7-34, 2019
5. Azamjah N, Soltan-Zadeh Y, Zayen F: Global trend of breast cancer mortality rate: A 25-year study. Asian Pac J Cancer Prev 20:2015-2020, 2019
6. Auster P, Boniol M, LaVecchia C, et al: Disparities in breast cancer mortality trends between 30 European countries: Retrospective trend analysis of WHO mortality database. BMJ 341:c3620, 2010
7. McCormack V, McKenzie F, Foerster M, et al: Breast cancer survival and survival gap apportionment in sub-Saharan Africa (ABC-DO): A prospective cohort study. Lancet Glob Health 8:e1203-e1212, 2020
8. O’Neil DS, Keating NL, Dusengimana JMV, et al: Quality of breast cancer treatment at a rural cancer center in Rwanda. JCO Glob Oncol 4:1-11, 2018
9. Oluwasanu M, Olopade OI: Global disparities in breast cancer outcomes: New perspectives, widening inequities, unanswered questions. Lancet Glob Health 8:e978-e979, 2020
10. World Bank Classification of Countries 2021. www.datahelpdesk.worldbank.org
11. Kosovo Agency of Statistics. www.ask.rks.gov.net
12. Oncology Clinic. www.shskuk.rks-gov.net
13. Islami DA: Breast Cancer. Our Data and Challenges. 1st Pan-Albanian Conference on Breast Cancer, 2019, Pristina, Kosovo.
14. Pace LE, Schleimer LE, Shyirambere C, et al: Identifying breast cancer care quality measures for a cancer facility in rural sub-Saharan Africa: Results of a systematic literature review and modified delphi process. JCO Glob Oncol 6:1446-1454, 2020
15. Shulman LN, Mpunga T, Talepa N, et al: Bringing cancer care to the poor: Experiences from Rwanda. Nat Rev Cancer 14:815-821, 2014
16. Organization PAH: Honduras Cancer Profile 2013. Pan American Health Organization, 2013. https://www.paho.org/en/documents/honduras-cancer-profile-2013
17. Perkins RB, Langrish SM, Cotton DJ, et al: Maternal support for human papillomavirus vaccination in Honduras. J Womens Health (Larchmt) 20:85-90, 2011
18. Kennedy LS, Bejarano SA, Onega TL, et al: Opportunistic breast cancer education and screening in rural Honduras. JCO Glob Oncol 2:174-180, 2016
19. Koh WJ, Anderson BO, Carlson RW: NCCN resource-stratified and harmonized guidelines: A paradigm for optimizing global cancer care. Cancer 126:2416-2423, 2020 (suppl 10)

Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rcw or ascopubs.org/go/authors/author-center.

Ilir Hoxha
Stock and Other Ownership Interests: LifestylediagnostiX

Dafina Ademi Islami
Consulting or Advisory Role: Roche Kosovo

Mary D. Chamberlin
Consulting or Advisory Role: Genomic Health International Research Funding: Archer (Inst)

No other potential conflicts of interest were reported.

ACKNOWLEDGMENT
The authors acknowledge the Dartmouth Hitchcock Fund For Global Oncology Research, Education, and Patient Support.

JCO Global Oncol 8:e2100424. © 2022 by American Society of Clinical Oncology
20. Anderson BO, Shyyan R, Eniu A, et al: Breast cancer in limited-resource countries: An overview of the breast health global initiative 2005 guidelines. Breast J 12:S3-S15, 2006 (suppl 1)
21. Duggan C, Dvaladze A, Rositch AF, et al: The breast health global initiative 2018 global summit on improving breast healthcare through resource-stratified phased implementation: Methods and overview. Cancer 126:2339-2352, 2020 (suppl 10)
22. Hoxha I, Busato A, Luta X: Medical practice variations in reproductive, obstetric, and gynecological care, in Johnson A, Stukel TA (eds): Medical Practice Variations. Boston, MA, Springer, 2016, pp 141-160
23. Richards MA, Westcombe AM, Love SB, et al: Influence of delay on survival in patients with breast cancer: A systematic review. Lancet 353:1119-1126, 1999
24. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 378:1707-1716, 2011
25. Akuoko CP, Armah E, Sarpong T, et al: Barriers to early presentation and diagnosis of breast cancer among African women living in sub-Saharan Africa. PLoS One 12:e0171024, 2017
26. UKPredict, 2021. https://breast.predict.nhs.uk/
27. Albert JM, Liu DD, Shen Y, et al: Nomogram to predict the benefit of radiation for older patients with breast cancer treated with conservative surgery. J Clin Oncol 30:2837-2843, 2012
28. Fyles AW, McCready DR, Manchul LA, et al: Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med 351:963-970, 2004
29. Hughes KS, Schnaper LA, Bellon JR, et al: Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: Long-term follow-up of CALGB 9343. J Clin Oncol 31:2382-2387, 2013
30. Overgaard M, Jensen MB, Overgaard J, et al: Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 353:1641-1648, 1999
31. Shulman LN, Wagner CM, Barr R, et al: Proposing essential medicines to treat cancer: Methodologies, processes, and outcomes. J Clin Oncol 34:69-75, 2016
32. Cortes J, Perez-Garcia JM, Llombart-Cussac A, et al: Enhancing global access to cancer medicines. CA Cancer J Clin 70:105-124, 2020
33. Mahmic-Kaknjo M, Jelicic-Kadic A, Utrobicic A, et al: Essential medicines availability is still suboptimal in many countries: A scoping review. J Clin Epidemiol 98:41-52, 2018
34. Robertson J, Barr R, Shulman LN, et al: Essential medicines for cancer: WHO recommendations and national priorities. Bull World Health Organ 94:735-742, 2016
35. Sharma R: Global, regional, national burden of breast cancer in 185 countries: Evidence from GLOBOCAN 2018. Breast Cancer Res Treat 187:557-567, 2021